GHRH analog - GHRH(1-29)
A 29-amino-acid peptide identical to the active fragment of natural GHRH; historically an FDA-approved drug (Geref).
| Class / type | GHRH analog - GHRH(1-29) |
|---|---|
| Category | Growth Hormone & Muscle |
| Status (Jul 2026) | Compounded (Rx) |
Sermorelin is a 29-amino-acid peptide identical to the active business end of natural GHRH. It has the most established medical history of the growth-hormone peptides - it was once an FDA-approved drug (Geref) used to assess and treat growth-hormone deficiency in children.
Today no finished FDA-approved sermorelin product is marketed; it is prescribed through compounding pharmacies, mostly off-label for adult GH optimization, sleep and recovery.
It binds GHRH receptors on the pituitary, prompting the gland to make and release growth hormone in a natural, pulsatile way while preserving the body's own feedback control. Its short half-life (~10-20 minutes) is part of why it's considered 'physiologic' rather than forcing a flat, sustained rise.
As a diagnostic and pediatric growth agent it has decades of clinical use and a supportive literature. For adult body-composition and anti-aging use the evidence is much thinner and largely anecdotal, though its mechanism and safety profile are well characterized.
Longest and most legitimate track record of the GH peptides, with a gentle physiologic action and prior FDA approval giving it a stronger legal footing (compounded rather than pure research-chemical).
Users report improved sleep, recovery, skin and energy.
Effects are milder than direct GH; it requires daily injection. Common effects are injection-site reactions, flushing, headache and occasional dizziness.
Compounded product quality varies by pharmacy, and adult anti-aging benefits are not well proven.
The former branded product (Geref) was discontinued for commercial, not safety, reasons. All current sermorelin is compounded and prescription-only, which places it on firmer legal ground than research-only peptides.
Its legitimacy / 'cleaner' legal footing (prior FDA approval) plus a gentle, physiologic profile.
Former FDA approval (Geref) discontinued ~2008 for commercial reasons. Today only compounded (503A/503B), prescription-only; stronger legal basis than research-only peptides.